A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Decatur, Hialeah, Hollywood, Houston, Lenexa, Marlton, Miami, Philadelphia, River Forest, San Antonio, Sugar Land, and Tomball, United StatesSee the 12 sitesAlso in 1 other country, 4 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 931 people enrolled
- Started
- 15 Jul 2024
- Ended
- 25 Sept 2025
- Type of study
- Interventional, 6 groups
- Treatments tested
- mRNA-1083
- Record updated
- 8 October 2026
Who can take part
- Age
- 50 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Investigator assessment that the participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures
- Participants of nonchildbearing potential may be enrolled in the study
- Participants who could become pregnant: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
- Have received an influenza vaccine in the previous season (since September 2023 for Part 1, since Sep 2024 for Part 2)
Who cannot take part
- Received corticosteroids at ≥10 milligrams (mg)/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study
- Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (e.g., infliximab), within 180 days prior to Day 1 or plans to do so during the study
- Received or plans to receive any vaccine authorized or approved by a local health agency within 28 days prior to Day 1 or plans to do so within 28 days post study injection
- Received a licensed seasonal influenza vaccine within 150 days prior to Day 1
- Received a licensed/authorized SARS-CoV-2 vaccine within 90 days prior to Day 1
- Received any investigational influenza vaccine, investigational coronavirus disease 2019 (COVID-19) vaccine, or investigational combination vaccine for influenza and COVID-19 within 12 months prior to Day 1. Participants from mRNA-1083-P201 Part 1 will also be excluded from Part 2; Other protocol-defined inclusion/exclusion criteria may apply
- Reported diagnosis or condition that is associated with increased risk of severe influenza disease or complications, including individuals with chronic medical conditions
- Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infections
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any of the following: mRNA vaccine or therapeutic; components of an mRNA vaccine or therapeutic; influenza vaccine; or components of an influenza vaccine, including egg protein
Where in United States
Also in 1 other country, 4 sites
- Cenexel IRADecatur, United States
- Indago Research & Health Center, IncHialeah, United States
- CenExel RCAHollywood, United States
- DM Clinical Research - Cyfair Clinical Research Center - PPDSHouston, United States
- JCCTLenexa, United States
- Hassman Research Institute - Berlin - CenExel - PPDSMarlton, United States
- Suncoast Research Group, LLC dba Flourish ResearchMiami, United States
- DM Clinical Research - PhiladelphiaPhiladelphia, United States
- DM Clinical Research - River ForestRiver Forest, United States
- Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, United States
- DM Clinical Research - SugarlandSugar Land, United States
- DM Clinical Research - Tomball MDCTomball, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65 years of age.
The 6 groups in the trial
- Part 1 Group 1 - mRNA-1083 Lot ATreatment being tested
Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 1.
Treatment: mRNA-1083
- Part 1 Group 2 - mRNA-1083 Lot BTreatment being tested
Participants will receive mRNA-1083 Lot B as a single injection on Day 1 in Part 1.
Treatment: mRNA-1083
- Part 1 Group 3 - mRNA-1083 Lot CTreatment being tested
Participants will receive mRNA-1083 Lot C as a single injection on Day 1 in Part 1.
Treatment: mRNA-1083
- Part 1 Group 4 - mRNA-1083 Lot DTreatment being tested
Participants will receive mRNA-1083 Lot D as a single injection on Day 1 in Part 1.
Treatment: mRNA-1083
- Part 2 Group 5 - mRNA-1083 Lot ATreatment being tested
Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 2.
Treatment: mRNA-1083
- Part 2 Group 6 - mRNA-1083 Lot ETreatment being tested
Participants will receive mRNA-1083 Lot E as a single injection on Day 1 in Part 2.
Treatment: mRNA-1083
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Adults ≥50 to <65 Years of Age
- Record updated
- 8 October 2026